Basics Amicus Therapeutics, Inc. Amicus Therapeutics Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of next-generation medicines. IPO Date: May 31, 2007 Sector: Healthcare Industry: Biotech Market Cap: $2.15B Activated in VL: True Average Daily Range Avg Daily Range: $0.24 | 2.67% Avg Daily Range (30 D): $0.16 | 2.57% Avg Daily Range (90 D): $0.14 | 2.19% Institutional Daily Volume Avg Daily Volume: 1.5M Avg Daily Volume (30 D): 3.71M Avg Daily Volume (90 D): 4.07M Trade Size Avg Trade Size (Sh.): 147 Avg Trade Size (Sh.) (30 D): 158 Avg Trade Size (Sh.) (90 D): 156 Institutional Trades Total Inst.Trades: 7,313 Avg Inst. Trade: $2.9M Avg Inst. Trade (30 D): $2.27M Avg Inst. Trade (90 D): $3.04M Avg Inst. Trade Volume: .26M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $3.57M Avg Closing Trade (30 D): $3.08M Avg Closing Trade (90 D): $4.03M Avg Closing Volume: 321.89K     News Aug 6, 2025 @ 12:30 PM Clinical Progress in Rare Disease Signals Long-Ter... Source: Prnewswire Jul 31, 2025 @ 11:00 AM Amicus Therapeutics Announces Second Quarter 2025 ... Source: Amicus Therapeutics Jun 3, 2025 @ 11:00 AM New Analysis of Pombiliti® (cipaglucosidase alf... Source: Amicus Therapeutics May 30, 2025 @ 11:00 AM Amicus Therapeutics to Present at Upcoming Investo... Source: N/A Feb 21, 2025 @ 6:00 PM Cell and Gene Therapies in Rare Disorders Market t... Source: Delveinsight Financials   TTM Q2 2025 Q1 2025 Basic EPS $-.08 $-.07 Diluted EPS $-.08 $-.07 Revenue $ $ 154.69M $ 125.25M Gross Profit $ $ 139.47M $ 113.55M Net Income / Loss $ $ -24.42M $ -21.69M Operating Income / Loss $ $ -9.47M $ -7.95M Cost of Revenue $ $ 15.22M $ 11.7M Net Cash Flow $ $ -22.72M $ -31.98M PE Ratio